News
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- DNA
- End of Treatment
- Hartwig Medical Database
- Hartwig Medical Foundation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …
In the media: Rarity – Personalised cancer treatment – fact not fiction
Imagine a world in which each person’s cancer is treated with a personalised, targeted medical treatment regimen. A world in …
Novel catalog interface Hartwig Medical Database with whole genome sequenced tumor genomes
Hartwig Medical Foundation has presented a novel catalog interface of the Hartwig Medical Database with whole genome sequenced tumor genomes: https://catalog.hartwigmedicalfoundation.nl. …
Complete DNA analysis for young adults with cancer
KWF finances the expansion of the infrastructure for cancer research in young adults with almost 4.5 million euros. These are …
Single WGS analysis of metastases is sufficient in most cases
DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in …
ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk …
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
Measuring the effects of radiotherapy on cancer may open up avenues for treatment
Radiotherapy works by damaging the DNA of cancer cells. It’s an effective strategy overall, but many cancers have subsets of …
Whole Genome Sequencing for cancer diagnostics clinically validated
Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular …
In the media: Genomeweb: Partial reimbursement for comprehensive DNA test in the Netherlands
This week, Genomeweb’s Precision Oncology News brought the news that the Dutch House of Representatives has recently unanimously decided to …
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.